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The final steps in the production of the type C retroviruses include assembly of the viral core particle and
release of virions from the surface of the infected cell. The core proteins are translated as part of one of two
precursors, Gag and Gag/Pol, which are cleaved by a virally encoded protease. We examined the interaction
between the processing of the human immunodeficiency virus type 1 Gag precursor and the membrane-based
assembly and budding of virions. Our results indicate that cleavage by the viral protease is initiated at the
membrane of the infected cell during virus release and that protease activity is required for virion release to
occur with maximum efficiency.
The proteins of the retroviral capsid are contained in two
precursors, Gag and Gag/Pol, which are cleaved to their
mature forms by the viral protease. The final stages in the
production of retroviruses include association of the Gag and
Gag/Pol precursors, both with the membrane of the infected
cell and with each other; activation of the virally encoded
protease; processing of the precursors; and the final assembly
and budding of virus particles (6, 26). Although some of these
events can occur independently of the others (e.g., protease-
mediated cleavage of the precursors may occur without mem-
brane association [3, 8, 15] and virus particles containing
unprocessed precursors may bud from the surface of infected
cells [5, 8, 6-18, 22, 27, 30, 31]), production of infectious virus
requires that these events occur in a coordinated fashion. We
examined the terminal phases in the budding of human
immunodeficiency virus type 1 (HIV-1) to define the interac-
tion between the assembly of virus particles and precursor
processing.
The exact timing of Gag and Gag/Pol processing during the
retrovirus life cycle is uncertain. Although cell-associated
precursor cleavage has been demonstrated for all type C
retroviruses studied (1, 4, 7, 9, 10, 12, 19, 21, 23-25, 32, 35), the
question of whether processing as part of virion formation
occurs at the membrane or solely within the virion remains
unanswered. We have previously reported that the processing
of the Gag precursor of HIV-1 which gives rise to virions
occurs either at the membrane of the infected cell or in the
virion immediately after budding (15). Studies with Moloney
murine leukemia virus have revealed both cell-associated
processing and the presence of precursors outside the cell
surface (1, 7, 21). In this report, we demonstrate that process-
ing of the Gag precursor of HIV-1 is initiated before the
assembled virus buds from the surface of the infected cell and
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that protease activity is required for budding to proceed with
maximum efficiency.
For these experiments, we used CEM cells, a human T-cell
lymphoma cell line (a gift of M. Cloyd, University of Texas,
Galveston), which were maintained in RPMI 1640 containing
10% (vol/vol) fetal calf serum. CEM cells were infected with
virus recovered after transfection of HeLa cells with the
full-length HXB2 infectious clone (28). Chronically infected
cell lines were produced as described previously (15).
Our previous studies indicated that the Gag precursor is
processed either at the membrane or within the virion, imme-
diately after the virus is released from the surface of the
infected cell (15). To determine the site of action of the
protease, we looked for unprocessed precursors in virus col-
lected at very short intervals after release from infected cells.
An aliquot containing 107 CEM cells chronically infected with
an HIV isolate (HIV-1G) was resuspended in iced phosphate-
buffered saline (PBS) and vortexed vigorously to remove
extracellular, mature virions associated with the cell mem-
brane. The cells were collected by centrifugation in a micro-
centrifuge and resuspended in 1 ml of fresh medium at 37°C.
The samples were then filtered immediately through a 0.45-
,um-pore-size syringe filter which retained the infected cells but
allowed the newly released virus to pass through. One-third of
the filtered supernatant was added to an equal amount of
radioimmunoprecipitation assay buffer with 4% sodium dode-
cyl sulfate (SDS), blocking any further protease activity. By
using this technique, we estimated that we were able to recover
virus which had left the cell for no more than 10 s. Another
one-third of the filtered aliquot was incubated at 37°C for 1
min before the addition of radioimmunoprecipitation assay
buffer with SDS, and the final one-third was incubated for 30
min before disruption. In this way, extracellular processing, if
required, could occur.
These samples were then subjected to Western (immuno-
blot) analysis with monoclonal antibodies directed against the
mature Gag proteins (Fig. 1). The samples were stained with


















FIG. 1. Processing of the Gag precursor of HIV-1 immediately
after release from infected cells. Virus was recovered from infected
cells as described in the text. The virion-associated protease was either
inactivated by addition of a radioimmunoprecipitation assay buffer
with 4% SDS immediately (10 s) after recovery or allowed to incubate
at 37°C for 1 or 30 min. The samples were subjected to Western
analysis, and the blots were stained with monoclonal antibodies
directed against p17 and p24 (A) or p6 (B).
protein (p17), the adjacent capsid protein (p24), (Fig. 1A), or
the carboxy-terminal p6 protein (28, 33, 34) (Fig. 1B). In each
case, processing appeared to be largely complete by the initial
time point (Fig. 1A and B). The aliquots removed before the
addition of SDS and allowed to incubate at 37°C for either 1 or
30 min appeared to be unchanged. Although a small amount of
unprocessed protein was present at the initial time point, this
persisted when the virus was incubated at 37°C, suggesting that
it represents membrane-associated protein which has passed
through the filter.
The virtual absence of unprocessed Gag protein in virions
harvested at 10 s after washing of the cells suggests that
precursor processing occurs either in the virion within this time
period or at the membrane, just before or during release. We
reasoned that proteolytic cleavage of the precursors at the time
of capsid formation could play a role in maximizing the
efficiency of budding, perhaps by inducing a conformational
change in the immature capsid, which is composed of unproc-
essed precursors. Alternatively, if processing is delayed until
after the newly formed virus leaves the surface of the infected
cell, the presence or absence of protease activity would have no
effect on the efficiency of virion release. We decided, therefore,
to examine the interaction between release of newly assembled
virions and precursor processing by interfering with protease
activity and observing the rate at which viral proteins leave the
cell. CEM cells chronically infected with HIV-1 were pulse-
labeled with [35S]methionine in the presence of various con-
centrations of an HIV-1 protease inhibitor (Fig. 2). The cells
were then resuspended in complete medium which also con-
tained the inhibitor. Aliquots of cells and medium were
removed at the end of the pulse period and at 1, 2, and 3 h
during the chase period. Viral proteins were recovered from
the infected cells and supernatant by immunoprecipitation
with serum obtained from an HIV-1-seropositive person. Pre-
viously, we have demonstrated that this antiserum is capable of
efficiently identifying the unprocessed Gag precursor (16). At
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FIG. 2. Pulse-chase analysis of viral proteins from HIV-1-infected
cells treated with an inhibitor of the viral protease. CEM cells
chronically infected with HIV-1 were grown in methionine-free me-
dium for 3 h and then labeled with 150 ,uCi of [35S]methionine per ml
(1,000 Ci/mmol; New England Nuclear, Boston, Mass.) for 30 min. The
radiolabeled cells were washed twice with iced PBS and suspended in
complete, unlabeled medium. The cells were grown either in a 100 ,uM
of concentration of a control peptide (C) or in a 100, 10, or 1 ,uM
concentration of the inhibitor beginning 3 h before labeling. The cells
were maintained at that concentration throughout the experiment. The
inhibitor of the HIV-1 protease used in these studies was SKF 107461
(17). The control peptide, EC15547-71-2, is a peptidomimetic inhibitor
which has structural and physical properties similar to those of SKF
107461 but is 100-fold less active in enzyme inhibition assays (data not
shown). Aliquots containing 4 x 106 cells and supernatant were
recovered at the end of the pulse period (lanes 1 and 5) and at 1 (lanes
2 and 6), 2 (lanes 3 and 7), and 3 (lanes 4 and 8) h after the cells were
transferred to complete medium. The cell fraction (lanes 1 to 4) was
separated from the virus fraction (lanes 5 to 8) by centrifugation, and
the radiolabeled viral proteins were isolated by immunoprecipitation




the highest concentration of the inhibitor (100,uM), Gag
processing was completely inhibited and no processing inter-
mediates were observed (lanes 1 to 4). In addition, no viral
proteins were seen in the supernatant at any time during the
3-h chase period. As the inhibitor concentration was decreased
below the threshold of protease inhibition, completely pro-
cessed viral proteins began to appear in the supernatant by the
end of the pulse period. At all concentrations of the inhibitor,
viral protein production was unimpaired. There was some
turnover of the precursor over time at the higher concentra-
tions of the inhibitor (100 and 10,uM; lanes 4 and 5). Another
peptidomimetic compound which does not inhibit the protease
at this concentration was used as a control (panel C); this
compound had no effect on either processing or the efficiency
with which viral proteins were released.
This correlation between the release of virions into the
supernatant and activity of the protease suggests a role for
precursor processing in maximizing the efficiency with which
virions are released from the surface of the infected cell. To
avoid any unanticipated pleiotropic effects of the inhibitor, we
extended these observations by examining the association
between precursor processing and release of viral proteins in a
virus encoding a mutant enzyme. For these studies, we con-
structed an infectious clone from the HXB2 molecular clone
(28) in which the proline which is usually present at position 79
of the protease was replaced with a threonine (P79T) (21a).
The P79T mutant was selected for analysis because the mutant
enzyme has an intermediate phenotype in a bacterial process-
ing assay (20) and although virus containing this substitution is
infectious for transformed T cells, virus spread through cell
culture is delayed. Infection ofCEM cells with virus encoding
this substitution resulted in maximum syncytium formation and
cell death at 21 days, compared with 7 days for the wild-type
virus (data not shown). As part of an attempt to determine the
mechanism behind this delay, we evaluated the rate at which
the Gag precursor was processed in cells infected by the P79T
mutant.
CEM cells were infected with supernatant virus recovered
from HeLa cells transfected with either wild-type or mutant
constructs (14). Virus particles produced by these infections
were collected by ultracentrifugation, analyzed by Western
blot, and found to contain only completely processed Gag
proteins (data not shown). Cells infected with either the
wild-type or the mutant virus were grown in methionine-free
medium for 3 h and then labeled continuously in medium
containing 150 ,uCi of [35S]methionine per ml. Cells and
supernatant were recovered at various time points, and the
viral proteins were immunoprecipitated with antiserum from
an HIV-1-seropositive person (Fig. 3). For the wild-type virus
(upper panel, lanes 1 to 9), both processed and unprocessed
cell-associated, labeled viral proteins were seen after 30 min of
labeling (lane 1). At this time, a small amount of the p24 capsid
protein was seen in the supernatant (lane 5). Labeled Gag
proteins, processing intermediates, and completely processed
p24 protein were seen in the infected cells (lanes 2 to 4) and
accumulating in the supernatant (lanes 6 to 8) over the rest of
the 3-h labeling period. In the cells infected with the P79T
mutant, however, both processing and the release of viral
proteins were delayed (lower panel, lanes a to h). Only the
unprocessed Gag precursor was seen in the infected cells
during the first hour of labeling (lanes a and b), and some
processing intermediates were apparent after 3 h (lane d).
There was no evidence of viral proteins in the supernatant
during the labeling period (lanes e to h).
To confirm these results, wild-type virus and the P79T
mutant were transiently expressed in HeLa cells by using the
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FIG. 3. Continuous labeling of CEM cells infected with wild-type
HIV or the P79T protease mutant. CEM cells were infected with either
wild-type HIV-1 derived from the HXB2 infectious clone (upper
panel, lanes 1 to 8) or the P79T mutant virus (lower panel, lanes a to
h). At the peak of viral infection, as measured by cell killing and
syncytium formation, the infected cells were washed in PBS and
transferred to methionine-free medium for 3 h. The viral proteins were
then continuously labeled with [35S]methionine. Aliquots of cells and
virus were recovered after 30 min (wild-type virus, lanes 1 and 5; P79T,
lanes a and e), 1 h (wild type, lanes 2 and 6; P79T, lanes b and f), 2 h
(wild type, lanes 3 and 7; P79T, lanes c and g), and 3 h (wild type, lanes
4 and 8; P79T, lanes d and h). Uninfected CEM cells were used as
controls (lanes 9 and i). The cell fraction of each aliquot (wild type,
lanes 1 to 4; P79T, lanes a to d) was separated from the virus fraction
(wild type, lanes 5 to 8; P79T, lanes e to h) by centrifugation, and the
radiolabeled viral proteins were recovered by immunoprecipitation.
calcium phosphate transfection method (14). Release of viral
proteins into the supernatant was measured by a p24 antigen
enzyme-linked immunosorbent assay (Abbott Laboratories,
Abbott Park, Ill.). Twenty-four hours after transfection, the
amount of p24 antigen was significantly less in the supernatant
from the cells transfected with the P79T mutant than in that
from cells transfected with the wild-type virus (data not
shown).
To determine more accurately the rate at which viral pro-
teins are released from cells infected with the P79T mutant, we
next performed pulse-chase experiments. Cells infected with
either the wild type or the P79T mutant were grown in
methionine-free medium for 1 h and pulse-labeled with 150
,uCi of [35S]methionine per ml. The cells were then washed
twice with PBS and transferred to unlabeled, complete me-
dium. Aliquots of cells and medium were removed at several
time points, and the viral proteins were recovered by immu-
noprecipitation. The samples were evaluated by SDS-poly-
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FIG. 4. Comparison between the rates at which viral protein is
released from cells infected with wild-type virus or P79T protease
mutant virus. CEM cells infected with either wild-type HIV-1 or the
P79T mutant were pulse-labeled with [35S]methionine and chased with
complete medium. Aliquots of supernatant were recovered at the end
of the pulse-labeling period (O h) and at 1, 3, 6, 9, 14, and 18 h after
transfer to complete medium. Viral proteins were immunoprecipitated
with serum from an HIV-1-seropositive person and subjected to
SDS-polyacrylamide gel electrophoresis. The radioactivity in the dried
gels was quantitated with a radioanalytical analyzing system (Ambis
Systems). Shown are the summed counts per minute of the radiola-
beled viral proteins in the cell-free supernatant of cells infected with
wild-type virus (solid line) and the P79T mutant (dashed line).
labeled viral proteins were released into the supernatant was
quantitated by a radioanalytical analyzing system (Ambis Sys-
tems, San Diego, Calif.) (Fig. 4). Viral proteins produced by
infection with the wild-type virus were released into the
supernatant with a half-life of approximately 90 min. In
contrast, the release of viral proteins from the cells infected
with the P79T mutant was slower; radiolabeled viral proteins
were first identified outside the cells after 9 h in complete
medium. It is of note that only completely processed Gag
proteins were found in the supernatant of the P79T-infected
cells. Therefore, a delay in processing is associated with a delay
in the release of viral proteins.
In summary, we examined the interaction between the
processing of the HIV-1 Gag precursor and the membrane-
based assembly and budding of virions. Although it has been
clearly demonstrated that mutations which block protease
activity do not prevent particle formation, it is also clear that
complete processing of the Gag precursor is required for
normal virus assembly and infectivity (5, 8, 16-18, 22, 27, 30,
31). Even partial inhibition of Gag processing results in
aberrantly assembled viruses (16), and mutations which block
cleavage at each of the processing sites in Gag disrupt normal
assembly (8).
A prerequisite for any linkage between protease activity and
release of viral proteins is that processing is initiated before
virion release. We examined such an association by trying to
identify the exact site of action of the viral protease. Specifi-
cally, we wanted to determine whether processing is initiated at
the membrane before virion release or whether protease
activity is delayed until after the virus has left the surface of the
infected cell. Our attempts to examine newly formed virus
particles revealed only completely processed precursors. In
addition, whether protease activity was inhibited chemically or
by a mutation in the protease, there was a close correlation
between a delay in processing and a delay in release of the
maturing virus particles. A recent report by Shin and cowork-
ers indicates that an integrase mutation which impedes pro-
cessing also delays release of viral proteins into the superna-
tant (29).
The data presented here indicate that processing of the Gag
precursor is initiated at the membrane of infected cells and
that the final steps of virus assembly are delayed when pro-
cessing is slowed. If any additional processing occurs after
virion release, it must happen over a very short period of time.
Cell-associated processing is a common feature of retrovirus-
infected cells (1, 4, 7, 9, 10, 12, 19, 21, 23-25, 32, 35), although
a link between processing and virion release has not been
made previously. In several systems, unprocessed viral proteins
have been seen in virions (1, 7, 21). Several reports indicate
that the efficiency with which protease-deficient Rous sarcoma
virus and Moloney murine leukemia virus Gag-containing
particles are released from the surface of infected cells is not
markedly diminished (2, 13, 36-38). However, these studies
were performed either with cell lines which produce very high
levels of viral proteins and/or with chimeric subviral constructs.
Since assembly of the viral core is likely dependent on the local
concentration of Gag and Gag/Pol precursors, moderate dif-
ferences in the efficiency of viral release could easily be
obscured in these systems. These differences may also be
difficult to identify in systems using chimeric constructs or
those expressing Gag in the absence of other viral proteins.
Therefore, we do not know if this represents experimental
variation or a fundamental difference in the assembly of these
viruses.
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